GPR120 agonists for treatment of inflammatory bowel disease
By developing a GPR120 agonist that does not cause internalization and degradation, compound formula (I), which significantly reduces symptoms and inflammation in inflammatory bowel disease, solves the problem that existing treatments are not effective enough and achieves high efficiency local therapeutic effect.
Patent Information
- Application Number
- CN202380023191.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-03
- Filing Date
- 2023-03-03
- Publication Date
- 2024-11-26
AI Technical Summary
Existing treatments for inflammatory bowel disease are not always effective and may bring multiple side effects that lead to patients not being able to get satisfactory control of the condition.
A structurally relevant GPR120 agonist, compound formula (I), was developed, which is concentrated in the ileum and colon after oral administration, and is able to effectively prevent or treat inflammatory bowel disease and bind to and After activation, no internalization and degradation will be caused, thereby maintaining strong agonistic activity.
The GPR120 agonist significantly reduces the symptoms of inflammatory bowel disease, including weight loss and disease activity index, significantly inhibits the severity of inflammation, and reduces systemic side effects due to its low systemic absorption and high gastrointestinal concentration, achieving Local treatment effect.
Smart Images

Figure BDA0005005675200000031 
Figure BDA0005005675200000051 
Figure BDA0005005675200000141
Abstract
Description
Technical Field
[0001] The present invention relates to GPR120 agonists for use in treating inflammatory bowel disease. Background Art
[0002] Inflammatory bowel disease (IBD) marks a group of chronic inflammatory disorders of the gastrointestinal tract, the most common of which are ulcerative colitis (UC) and Crohn's disease (CD). In ulcerative colitis, the inflammation is limited to the mucosal lining of the large intestine (colon) and rectum, while in Crohn's disease, the inflammation most commonly affects the ileum but can affect any part of the gastrointestinal tract, even the mouth, in a patchy distribution.
[0003] Both conditions share similar symptoms, such as diarrhea, abdominal pain, rectal bleeding, and weight loss. However, despite the similarities between them, there are some other symptoms that are different. For example, malnutrition is very common in Crohn's disease because the small intestine is responsible for the absorption of nutrients and the small intestine is one of the affected, in contrast, ulcerative colitis is associated with blood in stool and rectal bleeding, which are less common in Crohn's disease. More than 50% of people with CD suffer from folate and vitamin D deficiencies, while more than 50% of people with UC suffer from iron deficiency.
[0004] Inflammatory bowel disease affects men and women equally, and it usually starts in adolescence and about 25% of patients with IBD are less than 20 years old. In some cases, it may also occur in adulthood (Journal of Medicine and Life Vol. 12, No. 2, April to June 2019, pp. 113 to 122). Although the cause of inflammatory bowel disease is still largely unknown, it is caused by extremely complex interactions between genetic and environmental factors, dysregulated immune responses, and changes in the microbiome, but these factors are not enough to cause the disease alone. In order to diagnose this disease, clinical, endoscopic, histological and radiological tests are used (Zhang Y. et al. World J Gastroenterol 2014; 20 (1): 91-99).
[0005] Currently, treatment of inflammatory bowel disease is based on a stage-by-stage approach.
[0006] For mild to moderate Crohn's disease, the first step in treatment is the use of aminosalicylates, such as 5-aminosalicylic acid (5-ASA), also known commercially as mesalamine. If this does not show efficacy, antibiotics, corticosteroids, and immunosuppressive drugs are used as a last resort before hospitalization.
[0007] Conventional treatments for ulcerative colitis include 5-aminosalicylic acid, corticosteroids, and purine analogs (azathioprine and mercaptopurine). If these do not work, patients are treated with immunosuppressive drugs such as calcineurin inhibitors, tacrolimus, and TNF-α inhibitors (Baumgart DC et al. The Lancet 2007; 369(9573): 1641-57).
[0008] However, existing therapeutic strategies do not always lead to remission and may be associated with many side effects. Therefore, for a considerable number of patients, this debilitating condition is still far from being controlled in a satisfactory manner. Therefore, IBD is still associated with unmet medical needs in many patients (Gordon et al, Eur. J. Gastroenterol. Hepatol. 2015 (27), 804-812).
[0009] Therefore, there is a strongly felt need to develop new therapeutic approaches for treating inflammatory bowel disease with greater efficacy and fewer side effects.
[0010] Several studies have shown the beneficial effects of ω-3 polyunsaturated fatty acids administered as adjunctive therapy in the prevention or treatment of ulcerative colitis and Crohn's disease. It has also been demonstrated that ω-3 fatty acids are substrates for the production of protectins, resolvins, and maresins that can regulate and attenuate inflammatory processes and lead to remission of IBD, and therefore can be considered a new complementary approach to the treatment of these inflammatory conditions (Marton et al, International Journal of Molecular Science 2019, 20(19), 4851).
[0011] GPR120 is a member of the rhodopsin family of G protein-coupled receptors (GPRs) and has been shown to mediate some of the anti-inflammatory and insulin-sensitizing effects of omega-3 fatty acids (Young Oh, Cell. 2010 September 3; 142(5):687-698).
[0012] It has been shown that GPR120 is abundantly expressed in the human intestine in endocrine L cells, K cells or I cells, where it acts as an external sensor for free fatty acids. These cells are present in the intestinal villi and face the intestinal lumen that comes into contact with food (Furness, JB et al. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 729-740).
[0013] Other studies have determined that in the terminal ileum and proximal colon, not only endocrine cells but also all epithelial cells lining the villi express GPR120 (Paulsen et al, PLoS ONE 2014, 9(2):e88227, doi:10.1371 / journal.pone.0088227). Summary of the invention
[0014] As will be shown in the Experimental Section, the present inventors have unexpectedly identified a number of structurally related GPR120 agonists that are particularly effective in preventing or treating inflammatory bowel disease.
[0015] These compounds are poorly absorbed after oral administration and are concentrated in high concentrations in the ileum and colon, and thus can effectively act locally to prevent or treat inflammatory bowel disease.
[0016] Furthermore, the present inventors have found that, unlike other known GRP120 agonists, these compounds do not cause internalization and degradation of GPR120 following binding and activation of the receptor, and are therefore able to elicit and maintain potent agonistic activity.
[0017] Therefore, a first object of the present invention is a GPR120 agonist of formula (I) for use in preventing or treating inflammatory bowel disease in an individual,
[0018]
[0019] in:
[0020] R 1 It is CH3,
[0021] R 2 It is H.
[0022] R 3 is selected from F, Cl and CF3,
[0023] or
[0024] R 1 and R 2 are independently selected from substituted or unsubstituted phenyl or thiophene, and H, provided that R 1 or R2 At least one of is H, and
[0025] R 3 It's F.
[0026] Wherein when the phenyl or thiophene is substituted, the substituent is preferably selected from Cl, F or CH3, more preferably at position 2, 3 or 4 on the phenyl group or at position 3, 4 or 5 on the thiophene group.
[0027] A second object of the present invention is a pharmaceutical composition comprising a GPR120 agonist of formula (I) as described above, for use in preventing or treating inflammatory bowel disease in an individual.
[0028] A third object of the present invention is a method for preventing or treating inflammatory bowel disease, which comprises administering a therapeutically effective amount of a GPR120 agonist of formula (I) as described above to an individual in need thereof. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 The weight loss in % over time in the experimental group described in Example 1a) is shown. Figure 1 A) and DAI score ( Figure 1 B). DSS I, DSS II and DSS III represent the stages of disease development (acute / chronic). This experiment is described in Example 1 b).
[0030] Figure 2 Shown are the colon lengths measured on day 39 in the experimental group described in Example 1a) after mice were sacrificed as described in Example 1c).
[0031] Figure 3 Photographs of the endoscopic determination described in Example 1d) for each experimental group described in Example 1a) are shown.
[0032] Figure 4 The combined endoscopic scores described in Example 1d) for each experimental group described in Example 1a) are shown.
[0033] Figure 5 The colon thickening scores ( Figure 5 A) and vascular pattern score ( Figure 5 B).
[0034] Figure 6 The visible fibrin scores ( Figure 6 A) and mucosal surface granularity score ( Figure 6B).
[0035] Figure 7 Shown is the histological analysis as described in Example 1e) for each experimental group described in Example 1a). It shows histological sections stained with hematoxylin and eosin.
[0036] Figure 8 is the mean histological score for each parameter in the Rachmilewitz score shown in the table of Example 1e) for each experimental group described in Example 1a).
[0037] Fig. 9 A schematic diagram of GPR120 signaling is shown.
[0038] Fig.10 Western blot results of GPR120 and β-arrestin 2 for each experimental group described in Example 1a) are shown ( Fig.10 B) and densitometric analysis of western blots using Image J and the resulting ratio between the levels of co-immunoprecipitated β-arrestin2 and GPR120 for each experimental group ( Fig.10 A), as described in Example 1f).
[0039] Fig.11 Western blot results of GPR40 and β-arrestin 2 are shown ( Fig.11 B) and densitometric analysis of western blots using Image J and the resulting ratio between the levels of co-immunoprecipitated β-arrestin2 and GPR40 for each experimental group ( Fig.11 A), as described in Example 1f).
[0040] definition
[0041] According to the present invention, the term "prevention" refers to administration to an individual before a disease or pathological event is established or occurs in order to obtain partial or complete prevention of the disease or pathological event.
[0042] According to one embodiment of the invention, prevention is complete prevention, wherein the condition or pathological event is completely blocked.
[0043] According to an alternative embodiment of the invention, prevention is partial prevention, wherein the onset or occurrence of the disorder or pathological event is delayed or reduced in severity.
[0044] According to the present invention, the term "treating" refers to completely reversing or reducing the severity or progression of a condition or pathological event after it has been established or occurred.
[0045] According to the present invention, the term "individual" refers to a human or an animal, preferably a human.
[0046] According to the present invention, the term "GP120" refers to G protein-coupled receptor 120 (GPR120), also known as free fatty acid receptor 4. According to the present invention, the term "GPR120 agonist" refers to a compound that binds to GPR120 and activates the GPR120 signaling pathway.
[0047] According to the present invention, the term "individual" refers to a human or an animal, preferably a human. DETAILED DESCRIPTION
[0048] A first object of the present invention is a GPR120 agonist of formula (I) for use in preventing or treating inflammatory bowel disease in an individual,
[0049]
[0050] in:
[0051] R 1 It is CH3,
[0052] R 2 It is H.
[0053] R 3 is selected from F, Cl and CF3,
[0054] or
[0055] R 1 and R 2 are independently selected from substituted or unsubstituted phenyl or thiophene, and H, provided that R 1 or R 2 At least one of is H, and
[0056] R 3 It's F.
[0057] Wherein when the phenyl or thiophene is substituted, the substituent is preferably selected from Cl, F or CH3, more preferably at position 2, 3 or 4 on the phenyl group or at position 3, 4 or 5 on the thiophene group.
[0058] Preferably, the GPR120 agonist of formula (I) is selected from:
[0059] 7-(3-(N-(4-fluoro-2,6-dimethylphenyl)sulfamoyl)phenyl)heptanoic acid,
[0060] 7-(3-(N-(4-chloro-2,6-dimethylphenyl)sulfamoyl)phenyl)heptanoic acid,
[0061] 7-(3-(N-(4-trifluoromethyl-2,6-dimethyl-phenyl)sulfamoyl)phenyl)heptanoic acid,
[0062] 7-(3-(N-(6-fluoro-4-methyl-[1,1'-biphenyl]-3-yl)sulfamoyl)phenyl)heptanoic acid
[0063] 7-(3-{[4-fluoro-2-methyl-5-(thiophen-2-yl)phenyl]sulfamoyl}phenyl)heptanoic acid,
[0064] and
[0065] 7-(3-(N-(5-Fluoro-3-methyl-[1,1'-biphenyl]-2-yl)sulfamoyl)phenyl)heptanoic acid.
[0066] A particularly preferred GPR120 agonist of formula (I) for use according to the present invention is 7-(3-(N-(4-fluoro-2,6-dimethylphenyl)sulfamoyl)phenyl)heptanoic acid, also known as DFL23806.
[0067] Another object of the present invention is the novel GPR120 agonist 7-(3-{[4-fluoro-2-methyl-5-(thiophen-2-yl)phenyl]sulfamoyl}phenyl)heptanoic acid of formula (I).
[0068] As will be shown in the experimental section, the present inventors have discovered that the GPR120 agonists of formula (I) above are highly effective in preventing and treating inflammatory bowel disease.
[0069] Preferably, the inflammatory bowel disease is Crohn's disease or ulcerative colitis.
[0070] Administration of the GPR120 agonist used according to the present invention to an individual is carried out according to known methods.
[0071] Preferably, the administration is oral administration or rectal administration.
[0072] The present inventors have found that the therapeutic effect of GPR120 agonists on inflammatory bowel disease is highly dependent on the surface activity of the molecule at the site of inflammation in the gastrointestinal tract. Therefore, when GPR120 agonists are administered orally, it is critical to deliver sufficient amounts of active drug to the affected area for therapeutic efficacy. At the same time, the systemic availability of the compound is unavailable for therapeutic effect and should be reduced to a minimum to improve therapeutic efficacy and avoid any systemic side effects.
[0073] The inventors have also found that the GPR120 agonists of formula (I) according to the present invention have pharmacokinetic and stability characteristics that make them particularly suitable for administration by oral administration. In particular, as demonstrated in Example 2, the inventors have determined that when the GPR120 agonists of formula (I) are administered orally, they exhibit a pharmacokinetic profile characterized by very low systemic absorption and high concentrations achieved in the lower gastrointestinal tract, and are therefore suitable for exerting surface effects at the level of the gastrointestinal tract regions affected by IBD.
[0074] Furthermore, it was found that these GPR120 agonists have high stability in gastric and intestinal fluids and in intestinal microsomes, and finally, low permeability to Caco-2 (an immortalized cell line of human colorectal adenocarcinoma cells). Due to these characteristics, the GPR120 agonists of formula (I) achieve surface action at the level of the mucosal layer of the ileum and large intestine without the need for local delivery using controlled release formulations or gastric resistant formulations.
[0075] Therefore, preferably, the GPR120 agonist of formula (I) for use according to the present invention is administered orally.
[0076] Preferably, the GPR120 agonist of formula (I) for use according to the present invention is administered in the form of a pharmaceutical composition.
[0077] Preferably, the GPR120 agonist of formula (I) used according to the present invention is administered in the form of a pharmaceutical formulation which is not a controlled release formulation.
[0078] Preferably, the GPR120 agonist of formula (I) for use according to the present invention is administered in the form of a pharmaceutical composition which is not a gastro-resistant formulation.
[0079] Another object of the present invention is a pharmaceutical composition comprising a GPR120 agonist of formula (I) as defined above, and at least one pharmaceutically acceptable excipient, for use in preventing or treating inflammatory bowel disease in an individual, as described above.
[0080] Preferably, the pharmaceutical composition of the present invention is prepared into a suitable dosage form comprising an effective amount of the GPR120 agonist of formula (I) as described above, and at least one pharmaceutically acceptable excipient.
[0081] Preferably, the pharmaceutical composition of the present invention is suitable for oral administration or rectal administration.
[0082] Preferably, the pharmaceutical composition for rectal administration is in the form of a suppository, edema, gel or foam dosage form.
[0083] Preferably, the pharmaceutical composition for oral administration is in the form of granules, fibers, microgranules, tablets or capsules.
[0084] Preferably, the pharmaceutical composition for oral administration is not a controlled release formulation and / or a gastro-resistant formulation.
[0085] In this application, the expression "effective amount" means a dosage of a compound or composition sufficient to significantly achieve a desired clinical response.
[0086] The dosage and treatment regimen of a GPR120 agonist of formula (I) used in accordance with the present invention for any particular individual will vary according to a number of factors within the knowledge and expertise of the skilled artisan including, for example, the half-life of the particular GPR120 agonist used, the formulation and route of administration used, the age, weight, general health, sex and diet of the individual.
[0087] As described herein, the pharmaceutical composition of the present invention comprises a GPR120 agonist of formula (I) and at least one pharmaceutically acceptable excipient. As used herein, the pharmaceutically acceptable excipient is selected from solvents, diluents or other carriers, dispersants or suspending aids, surfactants, isotonic agents, thickeners or emulsifiers, preservatives, solid binders, lubricants, etc. suitable for the desired specific dosage form.
[0088] Some examples of pharmaceutically acceptable excipients that may be present in the compositions according to the present invention include, but are not limited to, sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; sterile water; Ringer's solution; buffered saline; dextrose solution; maltodextrin solution; ethanol; and phosphate buffered solution.
[0089] The dosage forms of the pharmaceutical compositions of the present invention can be prepared by techniques familiar to pharmaceutical chemists and include mixing, granulating, compressing, dissolving, sterilizing and the like.
[0090] Furthermore, the composition of the present invention can be suitably formulated using appropriate methods known in the art or by the methods disclosed in Remington's Pharmaceutical Science (latest edition), Mack Publishing Company, Easton Pa.
[0091] The dosage form may also contain other traditional ingredients, such as preservatives, stabilizers, surfactants, buffers, osmotic regulators, emulsifiers, sweeteners, colorants, flavoring agents, etc.
[0092] Another aspect of the present invention is a method for preventing or treating inflammatory bowel disease in an individual, comprising administering to the individual an effective amount of a GPR120 agonist of formula (I) as described above.
[0093] Experimental Section
[0094] Statistical analysis
[0095] In all experiments, statistical analysis was performed using GraphPad Prism 7 (GraphPad Software). Data are expressed as mean ± SD or ± SEM, and differences were considered statistically significant when P < 0.05. ANOVA multivariate analysis with post hoc correction was performed for all experiments.
[0096] Example 1 - Therapeutic Effects of 7-(3-(N-(4-fluoro-2,6-dimethylphenyl)sulfamoyl)phenyl)heptanoic acid (DFL23806) in a Mouse Model of Dextran Sodium Sulfate-Induced Colitis
[0097] a) Model establishment and processing scheme
[0098] A mouse model of colitis induced by administration of dextran sodium sulfate (DSS) (Wirtz S. et al. Nature Protocols; Vol. 2, No. 3, pp. 541-546; 2007) was used to study the therapeutic effect of orally administered DFL23806 on colitis.
[0099] Specifically, female C57 / B16 mice, 8 to 12 weeks old, were subjected to three oral cycles of 2.5% dextran sodium sulfate (DSS) (molecular weight, 40 kDa; MP Biomedicals) in the drinking water, with each cycle characterized by 7 days of DSS administration followed by 7 days of filtered purified water.
[0100] DSS administration induces clinical signs of disease immediately 1 day after treatment, with changes in tight junction protein expression and increased expression of proinflammatory cytokines. These moderate initial effects are followed by increasingly severe symptoms, which are even more pronounced in chronic models, as will be described below, including increased intestinal permeability, goblet cell depletion, epithelial erosions and ulcers, and severe bleeding. More specifically, the current DSS-induced colitis model is characterized by acute and chronic phases: acute clinical symptoms (diarrhea and / or severely bloody stools) are associated with the presence of erosions and inflammation. More importantly, the earliest histological changes manifest as the loss of one-third of the crypt base (day 3 after the first DSS administration), which progresses over time until the entire crypt is lost, leading to erosions on day 5. The earliest changes are very focal and unrelated to inflammation. Inflammation is a secondary phenomenon and becomes apparent only after the onset of erosions.
[0101] Animals treated with multiple cycles of DSS followed by cycles of water developed chronic colitis with the following histological features: areas of inflammation and erosion, inactivity, crypt aberrations, florid epithelial proliferation, and possible dysplasia. The clinical disease activity index correlated significantly with pathological changes in both the acute and chronic stages of the disease.
[0102] (Chassaing, B, Current ProtoCols in Immunnology2014, 104(1), Cooper, H.Set al, Laboratoty Investigation: a Journal of Technical Methods and Pathology1993, 69(2), 238-249, D'Alessio, S et al, Journal of Clinical Investigation 2014, 124(9), 3863-3878).
[0103] Starting from day 3 of DSS administration, mice were divided into 4 experimental groups, and each group received the following designated treatments:
[0104] - Group 1: DSS (n=8)
[0105] No treatment was used as negative control.
[0106] - Group 2: DSS + vehicle (n = 8)
[0107] Treatment with 20% v / v Dimethyl Sulfoxide (DMSO) and 80% v / v Phosphate Buffered Saline (PBS), 0.1 M, pH 8 (vehicle) was used as negative control.
[0108] - Group 3: DSS + DFL 90 mg / kg (n=8)
[0109] Treatment was with DFL23806 dissolved in vehicle at a dose of 90 mg / kg once daily.
[0110] -Group 4: DSS+5-ASA 60mg / kg (n=8)
[0111] Treatment with 5-aminosalicylic acid (5-ASA) in vehicle at a dose of 60 mg / Kg once daily was used as a reference positive control.
[0112] Vehicle, DFL23806 and 5-ASA were administered by oral gavage every morning using a plastic sterile feeding tube 20 ga x 30 mm. All mice were sacrificed on day 39.
[0113] b) Assessment of weight loss and DAI (Disease Activity Index) score
[0114] The DAI score was established based on a scale that takes into account different parameters characterizing the induction and progression of experimental colitis (RS Walmsley et al. Gut 1998; 43: 29-32).
[0115] Body weight, the presence of large amounts of blood in feces, and stool consistency were recorded every 2 days. Specifically, DAI was determined at each time point by scoring changes in: weight loss (0 = none, 1 = 1% to 5%, 2 = 5% to 10%, 3 = 10% to 20%, 4 = > 20%); stool consistency (0 = normal, 2 = loose, 4 = diarrhea); and rectal bleeding (0 = normal, 2 = occult bleeding, 4 = severe bleeding).
[0116] The results obtained showed that compared with the control (DSS group and DSS + vehicle group), the percentage of body weight loss ( Figure 1 A) and lowering DAI( Figure 1 B) In both respects, administration of DFL23806 showed a significant effect as early as day 7. Interestingly, DFL23806 was found to be even more effective than 5-ASA at certain time points.
[0117] c) Colon length measurement
[0118] Mice were sacrificed on day 39, and the colon of each mouse was collected and the colon length was measured as an additional parameter of intestinal inflammation.
[0119] The results were confirmed by colon length, indicating a significant inhibitory effect of DFL23806 and 5-ASA compared to the DSS+vehicle group ( Figure 2 ).
[0120] d) Endoscopic evaluation and scoring
[0121] On the day of sacrifice (day 39), mice were anesthetized with 2% isoflurane and underwent endoscopy to confirm the inflammatory grade. The experimental endoscopy setup (called the "Coloview system") consisted of a miniature endoscope (scope outer diameter 1.9 mm), a xenon light source, a triple chip camera, and an air pump to achieve regulated inflation of the mouse colon (all from KarlStorz, Tuttlingen, Germany). Endoscopic manipulations were observed on a color monitor, and a modified murine endoscopic index score for colitis severity was assigned based on colonic translucency (0 to 3 points), granular characteristics of the mucosa (0 to 3 points), morphology of vascular typing (0 to 4 points), and the presence of fibrin (0 to 4 points) as previously described by Dr. D'Alessio (D'Alessio, S. et al. J. Clin. Invest. 124, 3863-3878; 2014), resulting in a cumulative score of 0 (no signs of inflammation) to 16 (endoscopic signs of very severe inflammation).
[0122] The comprehensive endoscopic scores obtained showed that DFL23806 and 5-ASA were able to significantly inhibit chronic experimental colitis ( Figure 3 and 4 This was observed not only in the comprehensive endoscopic score ( Figure 4 ), and for colon thickness ( Figure 5 A) Vascular typing Figure 5 B) Visualization of fibrin ( Figure 6 A) and mucosal surface granularity ( Figure 6 B) was also observed. Increased mucosal granularity indicates edema and small erosions. Lamina propria edema is characterized by the accumulation of neutrophils and capillaries. These data suggest that promoting resolution of inflammation by oral administration of a selective GPR120 agonist (e.g., DFL23806) can help reduce neutrophil infiltration and mucosal edema.
[0123] e) Histological evaluation and scoring
[0124] Histological analysis was performed by a professional pathologist in a blinded manner to grade intestinal inflammation. More specifically, the colons of colitis mice in multiple experimental groups were evaluated for histological analysis using 2 μM paraffin-embedded sections stained with hematoxylin (Dako) and eosin (Diapath). The degree of inflammatory cell infiltration and mucosal damage was evaluated by a blinded pathologist using the RACHMILEWITZ score (Table 1) (Rachmilewitz, D. et al. Gastroenterology 122, 1428-1441; 2002).
[0125] As shown in Table 1, this scoring system takes into account five histological parameters without distinguishing between the proximal and distal colon: ulceration in whole colon sections, degree of ulceration, flogosis, degree of flogosis, and fibrosis. For each parameter, a score of 0 to 4 was assigned as shown in Table 1. In the present case, since fibrosis did not occur in the DSS-induced chronic colitis model (Rachmilewitz, D. et al. Gastroenterology 122, 1428-1441; 2002), this parameter was not evaluated. Table 1. Rachmilewitz score
[0126] ulcer 0 No ulcer 1 Mucosal involvement 2 Mucosal + submucosa involvement 3 Involvement of the muscularis propria 4 The entire wall is affected Extended ulcer 0 No ulcer 1 Point 2 Very small 3 Moderate 4 Extensive Flogosis 0 Does not exist 1 Very small 2 Mild 3 Moderate 4 severe Extended flogosis 0 Does not exist 1 Mucous membranes 2 Mucosa + submucosa 3 Mucosa + submucosa + muscle wall penetration 4 The whole wall Fibrosis 0 Does not exist 1 Mucous membranes 2 Mucosa + submucosa 3 Mucosa + submucosa + muscle wall penetration 4 The whole wall
[0127] Figure 7 Representative histological images in the Figures show deep ulcers with crypt loss and extensive inflammatory infiltrates in the DSS and DSS+vehicle groups. In addition, the results demonstrated that both DFL and 5-ASA significantly reduced the histological scores of ulcers, ulcer extent, flogosis, and flogosis extent in a comparable manner when compared to DSS+vehicle ( Figure 8 ).
[0128] f) Evaluation of DFL binding to GPR120 and GPR40
[0129] The efficiency of DFL in activating GPR120 and / or GPR40 receptors was tested.
[0130] Agonist-induced GPR120 can participate in multiple signaling pathways to regulate different physiological outcomes. After ligand binding, β-arrestin (e.g., β-arrestin 2) can associate with the cytoplasmic domain of GPR120 and couple the receptor to specific downstream signaling pathways ( Fig. 9). For this reason, we verified the efficiency of the agonists in activating GPR120 and GPR40 by immunoprecipitation. Colon lysates (about 900 μg protein) from 6 mice in each experimental group were pooled, pre-cleaned with protein A / G plus-agarose (Santa Cruz), and then incubated with antibodies for immunoprecipitation (anti-GPR120 or anti-GPR40, Abcam) for 16 hours at 4°C, followed by incubation with protein A / G plus-agarose for 5 hours. The agarose beads were then collected by centrifugation, washed four times with lysis buffer, and heated to 95°C for 5 minutes after adding Laemmli buffer. The resulting immunoprecipitates were separated by SDS-PAGE and probed with anti-β-arrestin 2 antibodies (Santa Cruz).
[0131] Following western blotting, blots were subjected to densitometry analysis using Image J. Fig.10 and Fig.11 The immunoprecipitated β-arrestin 2 and GPR120 ( Fig.10 ) or GPR40 level ( Fig.11 ) and the results of the blot.
[0132] The results showed that at day 39, DFL effectively activated GPR120; in fact, the association between GPR120 and β-arrestin2 was higher in the DSS+DFL group compared with the control group or the DSS+5-ASA60mg / Kg group ( Fig.10 ).
[0133] After immunoprecipitation with anti-GPR40 antibody, the results showed that there was no increase in the association of GPR40 with β-arrestin2 in the DSS+DFL group or in the DSS+5-ASA group compared with mice treated with DSS alone or DSS+vehicle ( Fig.11 ).
[0134] This confirms that DFL23806 is a GPR120-selective agonist and can mediate signaling through the β-arrestin pathway.
[0135] Example 2 - Pharmacokinetic evaluation of GPR120 agonists following oral administration
[0136] The objective of this study was to evaluate the plasma and tissue exposure of the following compounds after a single oral administration to mice:
[0137] 7-(3-(N-(4-fluoro-2,6-dimethylphenyl)sulfamoyl)phenyl)heptanoic acid (hereinafter referred to as DFL23806),
[0138] 7-(3-(N-(4-chloro-2,6-dimethylphenyl)sulfamoyl)phenyl)heptanoic acid (hereinafter referred to as DFL23914),
[0139] 7-(3-(N-(2,6-dimethyl-4-(trifluoromethyl)phenyl)sulfamoyl)phenyl)heptanoic acid (hereinafter referred to as DFL23922),
[0140] 7-(3-(N-(6-fluoro-4-methyl-[1,1'-biphenyl]-3-yl)sulfamoyl)phenyl)heptanoic acid (hereinafter referred to as DFL23916),
[0141] 7-(3-(N-(5-fluoro-3-methyl-[1,1'-biphenyl]-2-yl)sulfamoyl)phenyl)heptanoic acid (hereinafter referred to as DFL23917),
[0142] 7-(3-{[4-fluoro-2-methyl-5-(thiophen-2-yl)phenyl]sulfamoyl}phenyl)heptanoic acid (hereinafter referred to as DFL24102).
[0143] For each of the above compounds, nine male CD1 mice, approximately 6 / 7 weeks of age at the start of the treatment period, were treated orally by gastric gavage with 55 mg / kg of the test compound (adjusted for purity) dissolved in a vehicle consisting of 20% v / v dimethyl sulfoxide (DMSO) and 80% v / v phosphate buffered saline (PBS), 0.1 M, pH 8.
[0144] Retro-orbital comprehensive blood sampling was performed at 30 minutes, 1 hour, 2 hours, 6 hours, 8 hours and 24 hours before or after administration (three mice / time point) for plasma pharmacokinetic evaluation. Blood samples were collected in heparinized collection tubes. Samples were immediately put on ice and kept cool until centrifugation (10000g for 3 minutes at about +4°C). Approximately 50 μL of plasma was stored in a refrigerator at -80°C awaiting analysis.
[0145] All animal manipulations (including husbandry, health monitoring, restraint, drug administration, etc.) and ethical revisions were performed in accordance with current Italian regulations (Legislative Decree n. 26 of March 4, 2014) implementing Directive 2010 / 63 / UE on the protection of animals used in biomedical research.
[0146] After sample collection, the concentrations of the test compounds were bioanalyzed using HPLC-MS / MS methods, and the pharmacokinetic analysis of the compounds in plasma and tissues was performed based on the mean concentration data according to a standard non-compartmental approach using the Watson system (v 7.6, Thermo Fisher Scientific Waltham, MA, USA).
[0147] The pharmacokinetic parameters obtained for each compound tested are summarized in the following table:
[0148] Table 2. Pharmacokinetic parameters in mice after oral administration
[0149]
[0150] The biodistribution of DFL23806 in the proximal and distal colon was evaluated in male Swiss albino mice following a single oral dose of DFL23806 90 mg / kg.
[0151] The results obtained are summarized in the following table:
[0152] Colonic concentrations (ng / g) of DFL23806 following PO (90.0 mg / kg) dosing in male Swiss albino mice.
[0153] Time (hours) Average value (ng / g) Standard Deviation 1.00 68.28 37.38 4.00 3567.22 5018.47
[0154] Colon / plasma ratios of DFL23806 following PO (90.0 mg / kg) dosing in male Swiss albino mice.
[0155] Time (hours) average value Standard Deviation 1.00 1.63 1.60 4.00 64.20 60.70
[0156] As can be seen from the table, the DFL23806 concentration in the colon was higher than the corresponding DFL23806 concentration measured in plasma (ratio = 64.2).
[0157] These results suggest that the tested compounds concentrate in the colon and thus exert their activity locally.
[0158] Example 3 - Internalization of GPR120 after activation
[0159] We evaluated the internalization of human GPR120 after activation by compounds DFL23806, DFL23916, DFL23914, DFL23922, DFL23917, and DFL24102 in dose response curves at concentrations up to 100 μM using Enzyme Fragment Complementation (EFC) technology developed by DiscoverX using β-galactosidase. The results showed that for all tested compounds, the concentration of GPR120 agonist required to activate the receptor was significantly lower than the concentration that caused GPR120 internalization and subsequent degradation. In particular, DFL23806 had an AC50 of 3.9 μM and activated the internalization of the human GPR120 receptor with an efficacy of 59.1% at 100 μM.
[0160] The significant difference between the AC50 values for activation and internalization indicates that the receptor is not internalized immediately after binding of the compound and therefore treatment with a GPR120 agonist according to the invention does not result in downregulation of the receptor.
[0161] This feature is not found in other GPR120 agonists known in the prior art. For example, data on the molecules TUG-891 and GW9508 revealed that activated and internalized AC 50 The values were similar (0.065 μM and 0.051 μM, respectively, for TUG-891 and 6.8 μM and 9.6 μM, respectively, for GW9508).
[0162] These concentrations indicate that the receptor is rapidly internalized and switched after binding of either of these compounds. The delay in receptor internalization mediated by the GPR120 agonists of the present invention increases the potency of action because activated GPR120 is able to engage in prolonged signal transduction.
Claims
1. A GPR120 agonist of formula (I) for use in preventing or treating inflammatory bowel disease in an individual, in: R 1 It is CH3, R 2 It is H. R 3 is selected from F, Cl and CF3, or R 1 and R 2 are independently selected from substituted or unsubstituted phenyl or thiophene, and H, provided that R 1 or R 2 At least one of is H, and R 3 It's F. Wherein when the phenyl or thiophene is substituted, the substituent is preferably selected from Cl, F or CH3, more preferably at position 2, 3 or 4 on the phenyl or at position 3, 4 or 5 on the thiophene.
2. The GPR120 agonist for use according to claim 1, which is selected from: 7-(3-(N-(4-fluoro-2,6-dimethylphenyl)sulfamoyl)phenyl)heptanoic acid, 7-(3-(N-(4-chloro-2,6-dimethylphenyl)sulfamoyl)phenyl)heptanoic acid, 7-(3-(N-(4-trifluoromethyl-2,6-dimethyl-phenyl)sulfamoyl)phenyl)heptanoic acid, 7-(3-(N-(6-fluoro-4-methyl-[1,1'-biphenyl]-3-yl)sulfamoyl)phenyl)heptanoic acid, 7-(3-{[4-fluoro-2-methyl-5-(thiophen-2-yl)phenyl]sulfamoyl}phenyl)heptanoic acid, and 7-(3-(N-(5-Fluoro-3-methyl-[1,1'-biphenyl]-2-yl)sulfamoyl)phenyl)heptanoic acid.
3. The GPR120 agonist for use according to claim 1 or 2, which is 7-(3-(N-(4-chloro-2,6-dimethylphenyl)sulfamoyl)phenyl)heptanoic acid.
4. The GPR120 agonist for use according to claims 1 to 3, wherein the inflammatory bowel disease is ulcerative colitis or Crohn's disease.
5. The GPR120 agonist for use according to claims 1 to 4, wherein the GPR120 agonist is administered orally.
6. The GPR120 agonist for use according to claims 1 to 5, wherein the GPR120 agonist is administered in the form of a pharmaceutical composition which is not a controlled release formulation and / or a gastro-resistant formulation.
7. A pharmaceutical composition comprising a GPR120 agonist according to claims 1 to 3, and at least one inert pharmaceutically acceptable excipient, for use in preventing or treating inflammatory bowel disease in an individual.
8. The pharmaceutical composition for use according to claim 7, which is for oral administration.
9. A GPR120 agonist which is 7-(3-{[4-fluoro-2-methyl-5-(thiophen-2-yl)phenyl]sulfamoyl}phenyl)heptanoic acid.
Citation Information
Cited By
Application of GW9508 in preparation of medicine for treating rotavirus
CN120919101A
